Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ivabradine

FDA-approved product (solution, oral), marketed as Corlanor, Ivabradine Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ivabradine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cardiac preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ivabradine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ivabradine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cardiovascular Effects of Selective I(f)-Channel Blockade

    NCT00865917 · start 2008-11

    Registered record
    Registry ID
    NCT00865917
    Conditions
    Postural Orthostatic Tachycardia Syndrome
    Interventions
    beta-blocker (Metoprolol); I(f)-blocker (ivabradine); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2008-11
    Completion
    2010-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostural Orthostatic Tachycardia Syndrome
    Interventionbeta-blocker (Metoprolol); I(f)-blocker (ivabradine); Placebo
    PhasePhase 2
    Registry statusUnknown

  • Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals

    NCT00825123 · start 2008-10

    Registered record
    Registry ID
    NCT00825123
    Conditions
    Central Arterial Pressure
    Interventions
    Ivabradine; Metoprolol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2011-11-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Arterial Pressure
    InterventionIvabradine; Metoprolol; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure

    NCT01699776 · start 2008-04

    Registered record
    Registry ID
    NCT01699776
    Conditions
    Cardiac Failure
    Interventions
    Ivabradine; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2012-02
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Failure
    InterventionIvabradine; Digoxin
    PhasePhase 4
    Registry statusCompleted

  • Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

    NCT02441218 · start 2006-09

    Registered record
    Registry ID
    NCT02441218
    Conditions
    Chronic Heart Failure
    Interventions
    Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-09
    Completion
    2010-04
    Enrolment
    6,505

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure
    InterventionIvabradine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris

    NCT00202566 · start 2005-06

    Registered record
    Registry ID
    NCT00202566
    Conditions
    Angina Pectoris
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-06
    Completion
    2007-10
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngina Pectoris
    InterventionIvabradine
    PhasePhase 3
    Registry statusCompleted